Corporate Overview and Recent Market Performance of Regenxbio Inc. (RGNX)
Regenxbio Inc. (ticker RGNX) experienced a modest uptick of 3.5 % in its share price during the 24‑hour trading window that closed at 04:32 AM Central Europe on Thursday, 22 October 2026. At the time of reporting, one share of Regenxbio was available on major exchanges for approximately USD 7.17. The company’s liquidity is supported by a share supply of 66 million and a current market capitalization of USD 472 million.
Trading Activity
- 24‑hour volume: Approximately USD 9.7 million of Regenxbio shares were transacted in the last 24 hours.
- Price movement since month‑end: The stock has declined ‑6.09 % since the close of the previous month.
- Technical indicators:
- 200‑day simple moving average: USD 9.48
- 52‑week high: USD 16.19 (recorded on 22 January 2026)
- 52‑week low: USD 5.46 (recorded on 18 May 2026)
These figures illustrate a share that is still trading well above its recent low while approaching its historical peak, suggesting a potential upside if the company’s fundamentals continue to support the price.
Comparative Performance of Peer Stocks
The following table summarizes the 24‑hour performance of five peers listed in the same sector:
| Ticker | Recent Return | Current Price (USD) | Market Cap (USD mn) | P/E Ratio |
|---|---|---|---|---|
| RMR /The | +0.57 % | 17.33 | 562.2 | 41.77 |
| SHEN | ‑0.20 % | 9.76 | 562.5 | — |
| KRNY | +2.14 % | 9.06 | 560.4 | 15.38 |
| REAX | +11.23 % | 15.85 | 563.4 | — |
| CLYM | +11 % | 10.87 | 558.9 | — |
Regenxbio’s 3.5 % gain sits comfortably within the range of its peers, with a particularly notable performance from Real Remax (REAX) and Climb Bio (CLYM), both posting double‑digit gains.
Company Profile
Regenxbio Inc. is a biotechnology firm headquartered in Rockville, United States, with a global footprint. The company specializes in the development, commercialization, and licensing of recombinant and adeno‑associated virus (AAV) gene therapy products. Its portfolio focuses on leveraging advanced gene‑editing technologies to provide innovative treatment options for patients suffering from genetic disorders. Regenxbio went public on the Nasdaq stock exchange on 17 September 2015 and has since positioned itself as a pioneer in the rapidly evolving gene‑therapy market.
For further information on the company’s initiatives, products, and research pipeline, stakeholders may visit the official website at www.regenxbio.com .
This concise corporate snapshot provides a clear view of Regenxbio’s recent market dynamics, comparative peer performance, and strategic focus within the biotechnology landscape.
